Proficiency testing (PT) for labs performing HIV viral load (VL) is critical to determining that acceptable patient monitoring standards are being established. Current PT programs utilize infectious material which requires a cold chain for shipping and local laboratory storage. We set out to develop QCMs to reduce the infectious risk of the QCM and overall cold chain requirements.
A Clade C virus from the NIAID EQAPOL program was heat inactivated and shown inability to replicate, as determined by VL and p24 Ag testing; then lyophilized at 50,000 copies/ml. Testing was performed at four storage temperatures (-20°C, 4°C, 23°C, 30°C) at seven time points. Linear modeling was performed to make descriptive statistics (e.g., estimation of means) and a descriptive evaluation of the means for storage temperatures and time points at the alpha 0.05 level.
The heat-inactivated non-lyophilized viral material showed a VL of 4.698 (-05.=4.198 and +0.5=5.198) Log 10 (copies/ml) during 12 months of repeat testing under -800C conditions. Shown below are VL results for the lyophilized material held at different storage conditions over time and then tested. We found statistical evidence of a 0.007 Log10 increase per week of storage and that month 6 VL was higher than the average time point VL (see Figure 1). There was no statistical evidence of storage temperature differences. The model based means for storage temperatures range from 4.26 – 4.42 Log10 copies/ml and the model based means for the time points range from 4.28 – 4. 49 Log10 copies/ml. Displayed in Figure 1 below are the VL results for the lyophilized material held at different storage conditions over the various time points. The average VL is 4.38 with the standard acceptance criteria of +/- 0.5 Log10 copies/ml at 3.88 and 4.88.
These data we collected provides a proof of concept that the heat inactivated and lyophilized material remains stable and well within a the 0.5 Log10 acceptance criterai at all temperature storage conditions for up to six months. Studies are underway to determine suitably of this material for use in quality assessment of drug mutation sequencing assays. Reducing cold chain requirements, shipping costs and infectious status of QCMs offers significant improvements to current PT approaches. Work supported by NIAID EQAPOL HHSN27220170061C.